Core Viewpoint - MoonLake Immunotherapeutics experienced a significant decline in its stock price, dropping over 80% following disappointing results from two late-stage trials of its drug sonelokimab for hidradenitis suppurativa, raising concerns about the drug's regulatory and commercial viability [4]. Group 1: Company Overview - MoonLake Immunotherapeutics is under investigation by Faruqi & Faruqi, LLP, a national securities law firm, for potential claims related to the significant losses suffered by investors [3]. - The firm has a history of recovering hundreds of millions of dollars for investors since its establishment in 1995 [3]. Group 2: Trial Results - The first late-stage trial of sonelokimab showed a statistically significant improvement over placebo, but the benefit margin did not meet investor expectations [4]. - The second trial failed to meet its primary endpoint, attributed to an unexpectedly high placebo response, leading to skepticism regarding the drug's future [4]. Group 3: Market Reaction - The disappointing trial results prompted a sharp sell-off in MoonLake's stock, reflecting analysts' doubts about the drug's regulatory path and commercial potential [4].

Core Insights - MoonLake Immunotherapeutics is under investigation for potential violations of federal securities laws following disappointing results from its Phase 3 VELA trials for sonelokimab, a treatment for inflammatory diseases [1][2][3] Company Overview - MoonLake Immunotherapeutics is a clinical stage biotechnology company focused on therapies for inflammatory skin and joint diseases [2] Recent Developments - On September 29, 2025, MoonLake reported week 16 results from the VELA Phase 3 trials, which were disappointing and raised concerns about the drug's regulatory approval and commercial viability [3] - Following the announcement, MoonLake's stock price plummeted by $55.75 per share, nearly 90%, from $61.99 on September 28, 2025, to $6.24 on September 29, 2025 [3] Legal Context - Bleichmar Fonti & Auld LLP is investigating the situation and encourages investors to seek additional information regarding potential legal options [1][4]

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against MoonLake Immunotherapeutics for possible violations of federal securities laws and unlawful business practices, following a significant drop in the company's stock price after a trial report [1][2]. Investigation Details - The investigation focuses on whether MoonLake has engaged in unlawful business practices that may have led to financial losses for investors [2]. - The firm is encouraging investors who suffered losses to contact them for further discussion on their legal rights and options [1][3]. Recent Events - On September 29, 2025, MoonLake filed a current report with the SEC, revealing that its VELA-2 trial did not achieve statistical significance due to unexpected results in the placebo group, leading to a stock price decline of 89.9% on the same day [6].

Core Insights - MoonLake Immunotherapeutics is under investigation by Block & Leviton for potential securities law violations following a significant drop in share price after disappointing Phase 3 trial results [2][4]. Company Performance - Shares of MoonLake Immunotherapeutics fell over 85% in pre-market trading on September 29 due to the failure of one Phase 3 trial to meet its primary endpoint and modest gains in another trial compared to placebo [2]. - The Phase 3 data is considered to fall short of the previously touted Phase 2 MIRA trial results and is lagging behind competing drugs, raising concerns about the drug's commercial viability [2]. Legal Actions - Block & Leviton is investigating the public statements made by MoonLake regarding its drug trials and may file an action to recover losses for investors [4]. - Investors who have lost money on their MoonLake investments are encouraged to contact Block & Leviton for potential recovery options [5]. Investor Eligibility - Any individual who purchased common stock of MoonLake Immunotherapeutics and experienced a decline in share value may be eligible to participate in the investigation, regardless of whether they have sold their shares [3]. Whistleblower Information - Individuals with non-public information about MoonLake are encouraged to assist in the investigation or report to the SEC under the whistleblower program, with potential rewards of up to 30% of any successful recovery [6]. Firm Reputation - Block & Leviton is recognized as a leading securities class action firm, having recovered billions for defrauded investors and representing many top institutional investors [7].

Core Viewpoint - MoonLake Immunotherapeutics is under investigation for potential violations of federal securities laws following disappointing results from its Phase 3 VELA trials for sonelokimab, leading to a significant drop in stock price [1][3]. Company Overview - MoonLake Immunotherapeutics is a clinical stage biotechnology company focused on therapies for inflammatory skin and joint diseases [2]. Trial Results - On September 29, 2025, MoonLake reported week 16 results from the VELA Phase 3 trials, which were disappointing and raised concerns about the drug's regulatory approval and commercial viability [3]. - The stock price plummeted by $55.75 per share, nearly 90%, from $61.99 on September 28, 2025, to $6.24 on September 29, 2025, following the announcement [3]. Legal Implications - Investors in MoonLake are encouraged to seek additional information regarding potential legal options due to the investigation [1][4]. - Bleichmar Fonti & Auld LLP, a leading law firm in securities class actions, is representing affected shareholders on a contingency fee basis [6].

Core Insights - The health care sector is experiencing a trend of oversold stocks, presenting potential buying opportunities for undervalued companies [1][2] Group 1: Oversold Stocks - MoonLake Immunotherapeutics (NASDAQ: MLTX) has an RSI of 21.5, with a stock price drop of approximately 86% over the past month, reaching a 52-week low of $5.95. The stock saw a 13% increase to close at $8.43 [3][7] - CorVel Corp (NASDAQ: CRVL) has an RSI of 27.2, with a stock price decline of around 14% over the past month, hitting a 52-week low of $72.15. The stock rose 0.6% to close at $73.83 [4][7] - Harmony Biosciences Holdings Inc (NASDAQ: HRMY) has an RSI of 28.9, with a stock price decrease of about 24% over the past month, reaching a 52-week low of $26.26. The stock gained 2% to close at $27.28 [4][7] Group 2: Company Updates - MoonLake Immunotherapeutics reported week-16 results from its Phase 3 VELA-1 and VELA-2 trials, using HiSCR75 as the primary endpoint [7] - CorVel's CFO Brandon T. O'Brien stepped down, impacting the company's stock performance [7] - Harmony Biosciences Holdings announced topline results from its Phase 3 RECONNECT Study for ZYN002 in Fragile X syndrome, highlighting a catalyst-rich pipeline and plans for future trials [7]

Core Insights - The health care sector is experiencing a trend of oversold stocks, presenting potential buying opportunities for undervalued companies [1][2] Group 1: Oversold Stocks - MoonLake Immunotherapeutics (NASDAQ: MLTX) has an RSI of 21.5, with a stock price drop of approximately 86% over the past month, reaching a 52-week low of $5.95. Recent price action saw a 13% increase, closing at $8.43 [3][7] - CorVel Corp (NASDAQ: CRVL) has an RSI of 27.2, with a stock price decline of around 14% over the past month, hitting a 52-week low of $72.15. The stock rose 0.6% to close at $73.83 [4][7] - Harmony Biosciences Holdings Inc (NASDAQ: HRMY) has an RSI of 28.9, with a stock price decrease of about 24% over the past month, reaching a 52-week low of $26.26. The stock gained 2% to close at $27.28 [4][7] Group 2: Company Developments - MoonLake Immunotherapeutics reported week-16 results from its Phase 3 VELA-1 and VELA-2 trials, using HiSCR75 as the primary endpoint [7] - CorVel's CFO Brandon T. O'Brien stepped down, impacting the company's stock performance [7] - Harmony Biosciences released topline results from its Phase 3 RECONNECT Study for ZYN002 in Fragile X syndrome, highlighting a catalyst-rich pipeline and plans for future trials [7]

Core Insights - MoonLake Immunotherapeutics experienced a significant decline in its stock price, dropping over 80% following disappointing results from two late-stage trials of its drug sonelokimab for hidradenitis suppurativa [4] Company Overview - MoonLake Immunotherapeutics is currently under investigation by Faruqi & Faruqi, LLP for potential claims related to the significant losses suffered by investors [3] - The company is listed on NASDAQ under the ticker MLTX [3] Clinical Trial Results - One of the late-stage trials showed a statistically significant improvement over placebo; however, the margin of benefit did not meet investor expectations [4] - The second trial failed to meet its primary endpoint, attributed to an unexpectedly high placebo response, raising concerns about the drug's regulatory path and commercial viability [4] Market Reaction - The disappointing trial results led to skepticism from analysts and triggered a sharp sell-off in the market, reflecting investor concerns about the future of MoonLake's drug development [4]

New York, New York--(Newsfile Corp. - October 5, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into MoonLake Immunotherapeutics (NASDAQ: MLTX) for potential violations of the federal securities laws. If you invested in MoonLake, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/moonlake-immunotherapeutics.Why Is MoonLake being Investigated?MoonLake is a clinical stage biotechnology company focusing on therapies to addres ...

Core Viewpoint - MoonLake Immunotherapeutics is under investigation for potential violations of federal securities laws following disappointing results from its Phase 3 VELA trials for sonelokimab, leading to a significant drop in stock price [1][3]. Company Overview - MoonLake Immunotherapeutics is a clinical stage biotechnology company focused on therapies for inflammatory skin and joint diseases [2]. Trial Results - On September 29, 2025, MoonLake reported week 16 results from the VELA Phase 3 trials, which were disappointing and raised concerns about the drug's regulatory approval and commercial viability [3]. - The stock price plummeted by $55.75 per share, nearly 90%, from $61.99 on September 28, 2025, to $6.24 on September 29, 2025, following the announcement of the trial results [3]. Legal Implications - Investors in MoonLake are encouraged to seek legal options due to the potential violations of securities laws related to the trial results [1][4]. Law Firm Background - Bleichmar Fonti & Auld LLP is a leading international law firm specializing in securities class actions and shareholder litigation, with a strong track record of recovering significant amounts for clients [6].